FDA Greenlights Kythera’s Kybella
In a much anticipated approval, the FDA has given its nod to Kythera's Kybella to treat double chins.
In a much anticipated approval, the FDA has given its nod to Kythera's Kybella to treat double chins.
Two new clinical analyses examine how simultaneous, on-label 64-unit onabotulinumtoxinA treatment of the upper face delivers natural-looking, durable, and predictable outcomes across diverse patient populations and multiple treatment cycles.